Evidence map›Paper›PMID 41069284›Full record

ArticleDiabetes, obesity & metabolism2026

Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.

Hiroyuki Hisada, Kazuhiko Ikeuchi, Yosuke Tsuji, Nobutake Yamamichi, Naomi Kakushima, Kazuya Okushin, Seiichi Yakabi, Chihiro Takeuchi, Daisuke Ohki, Hiroya Mizutani and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hiroyuki HisadaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-6184-2215
Kazuhiko IkeuchiDepartment of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yosuke TsujiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobutake YamamichiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naomi KakushimaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kazuya OkushinDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Seiichi YakabiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Chihiro TakeuchiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daisuke OhkiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroya MizutaniDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuko MiuraDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Dai KubotaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takeya TsutsumiDepartment of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

JST, PRESTO JPMJPR23R1
6 · The paper itself

Abstract

aimsWhile discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1RAs) before esophagogastroduodenoscopy (EGD) is not universally mandated, safety concerns persist. Evidence remains insufficient for managing specific patient subgroups, particularly in Asian populations. We aimed to provide evidence for stratified risk assessment in a large Japanese cohort. MATERIALS AND

methodsThis nationwide retrospective cohort study used the Japan Medical Data Center database. We performed 1:4 propensity score matching based on age, sex, insulin use, HbA1c level, chronic respiratory disease, and body mass index to compare patients with diabetes receiving GLP-1RAs (n = 3568) with non-users (n = 14 246). Respiratory and severe complications within 14 days post-EGD were assessed via logistic regression.

resultsGLP-1RA was not associated with an increased risk of overall (0.39% vs. 0.50%; odds ratio [OR] 0.79, 95% confidence interval [CI] 0.44-1.40; p = 0.41) or severe (0.11% vs. 0.077%; 1.45, 0.46-4.56; p = 0.52) respiratory complications. While no subgroup analysis reached statistical significance, numerical trends towards a higher risk were observed in new users (OR 1.43; 95% CI, 0.51-3.98) and patients with severe diabetes (OR 1.28; 95% CI, 0.64-2.52).

conclusionsGLP-1RA was not associated with increased post-EGD respiratory complications, suggesting that routine discontinuation may be unnecessary for many stable, long-term users. However, our findings do not support a uniform conclusion of safety for all subgroups. The non-significant trends in new users and patients with severe diabetes warrant a cautious, individualised approach for these potentially vulnerable populations. Further research is needed to definitively clarify this risk.

Indexed as

Diabetes Mellitus, Type 2Endoscopy, Digestive SystemGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsRespiration DisordersRespiratory Tract DiseasesAdultAgedEast Asian PeopleFemaleHumansJapanMaleMiddle AgedRetrospective StudiesGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentscomplicationsesophagogastroduodenoscopyglucagon‐like peptide‐1 receptor agonistpoor glycaemic control

Identifiers

PMID41069284
PMCPMC12673464

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.